Inulin: Bowel Regularity, IBS Evidence and Digestive Tolerance

Key takeaways

  • Inulin is a fermentable fiber. Its source, chain-length distribution and accompanying ingredients matter
  • A defined native chicory inulin preparation has an EU stool-frequency food claim at 12 g/day; it is not approval to treat every cause of constipation (claim conditions)
  • Positive trials have commercial support, small samples or other design limits. This review does not establish a dependable independent treatment benefit (Micka; Puhlmann; Watson)
  • Inulin can increase gas. More fermentation or more bifidobacteria does not itself establish less pain or better functioning (acute MRI study; microbiome study)
  • Inulin, short-chain FOS, oligofructose and blends differ; one preparation cannot automatically inherit another’s results (ingredient distinctions; blend trial)

Inulin is a fermentable fiber with some positive bowel trials and a narrowly defined European food claim. Results vary by preparation and population. Major positive adult studies have commercial support; small samples, carryover and outcome-analysis limits also matter. A blend’s symptom signal and an acute reduction in MRI gas do not establish inulin-alone IBS treatment. This review does not establish a dependable general supplement regimen for constipation or IBS, and its financial screen is not evidence that inulin cannot help (EU claim; adult trial; IBS blend; MRI experiment).

Contents

Evidence summary · What it is · Forms and grades · How it works · Hype versus evidence · Benefits by claim · What works · Risks · Interactions · Who should avoid · Studied doses · Laboratory evidence · Funding · Regulation · FAQs · Sources

Evidence summary

Grades concern the exact claim and the evidence eligible after funding checks. A commercially supported result is described accurately but does not establish this article's independent benefit verdict. A declaration of no competing interests does not resolve an unidentified product supplier or missing financing information.

ClaimEvidenceSourceFunding/conflictStrength
Defined native chicory inulin increases stool frequencyFavorable EFSA assessment and EU-authorized food claimEFSA 2015; EU regulationManufacturer application; underlying studies not an independently funded evidence setHigh confidence in regulatory fact; independent clinical estimate insufficient
Improves adult constipation Positive short crossover trials; selection, carryover and analysis limits Micka 2017; Puhlmann 2025 BENEO or Sensus funding and company authors Insufficient independent evidence; excluded from independent benefit basis
Improves bowel function in everyoneMixed small studies; population-specific reviewWatson 2019; AHRQ 2025Sensus-funded trials; publicly commissioned review does not erase underlying conflictsUniversal claim unsupported
Treats constipation-predominant IBS 34-person, 50:50 inulin/oligofructose blend; symptom-severity change signal Akçalı 2025 Unnamed private supplier; cash and purchase/donation unresolved Preliminary blend evidence; stool-form, overall QOL-change and depression-change tests null
Improves children’s constipation Small agave trial in severe cerebral palsy; hard-stool comparison favorable, frequency not established García Contreras 2020 No external funding declared; researcher furnished named products, payment terms unknown Insufficient for routine pediatric use
Repairs an unhealthy microbiomeMicrobial changes in a commercially sponsored cohortVandeputte 2017BENEO funding and employeesInsufficient for “repair” or disease prevention
Fermentation can increase colonic gasAcute MRI experimentGunn 2022Public grants; indirect ties and procurement gapModerate for physiology

What it is

Inulin is a family of fructose-rich carbohydrates, rather than one uniform molecule. Human digestive enzymes do not readily break its characteristic linkages, allowing it to reach the colon and become a microbial substrate. Chicory roots are a commercial source; other plant-derived preparations have different structures and chain-length distributions. The FDA's ingredient assessment distinguishes these materials by source, processing and chemical properties. FDA science review

This review concerns oral food and supplement ingredients. It does not treat a spoonful of purified powder as equivalent to a serving of vegetables, a complete nutritional formula or a drug. The clinical question is whether adding a specified preparation improves a meaningful digestive outcome compared with an appropriate control.

Forms and grades

PreparationWhat distinguishes itWhy the distinction matters
Native chicory inulin A distribution of shorter and longer fructans, with small amounts of sugars The EU claim defines a mean degree of polymerization of at least 9 (legal composition)
Long-chain or high-performance inulinProcessing enriches longer chainsIt is not automatically dose-equivalent to native inulin or a short-chain preparation
OligofructoseShorter fructans, including material obtained by hydrolyzing inulinIt overlaps chemically with the inulin family but has its own trial and regulatory record
Sucrose-derived short-chain FOSManufactured short fructans with a more restricted compositionResearch on this preparation cannot be reassigned to every inulin powder
Agave-derived preparationsA different plant source; structure and specification require checking“Agave inulin” on a study label does not establish equivalence to the EU-defined chicory ingredient
Inulin plus other fibers or microbesA combination interventionAny improvement belongs initially to the tested combination

Degree of polymerization, or DP, describes chain length. Definitions and commercial mixtures overlap, so an arbitrary cutoff should not be used to turn every published “inulin-type fructan” trial into an inulin-alone trial. FDA ingredient distinctions, EU compositional conditions

Useful label information includes the source, actual grams of ingredient and fiber, other fermentable ingredients, and whether a named formulation matches the one studied. “Clinical grade,” “organic” and a trademark do not answer the clinical question. This review does not establish a superior brand.

How it works

Inulin supplies material that intestinal microbes can use. Fermentation produces metabolites and gas; possible effects on bacterial mass and stool properties provide a rationale for bowel studies. It is soluble but generally much less viscous than gel-forming fibers, so sharing the word “fiber” does not mean sharing every physical effect. FDA science review

A stool-sample change can show a microbial response without demonstrating that a person feels better. In Gunn’s IBS experiment, adding psyllium reduced MRI gas after inulin without establishing significant pain or bloating relief. Patient outcomes require their own controlled assessment (microbial analysis; human MRI results).

Hype versus evidence

“Prebiotic” does not identify a patient’s need or an effective personalized regimen. The microbiome analysis found associations rather than a validated stool-test threshold for treatment selection (original analysis).

“Approved in Europe” needs its full conditions. Native chicory inulin has a defined stool-frequency food claim. The EU refused a different Frutalose oligofructose claim because the submitted evidence did not establish an effect under the proposed conditions. That is neither a blanket no-effect verdict nor a reason to transfer the native-inulin claim to every neighboring preparation (native inulin authorization; Frutalose decision).

Academic affiliation does not settle who paid. The adult bowel studies include ingredient-business funding and company employees. Blinding or a stated absence of sponsor influence is relevant to validity but does not remove that financial relationship (Micka disclosure; Puhlmann declarations; Watson declarations).

Short selected studies do not characterize uncommon allergy, prolonged use or every special population and medicine combination. Puhlmann reported possible gas, bloating and cramps; one food-associated allergy report cannot supply an incidence estimate (trial harms; case report).

Benefits by claim

Adult constipation and low stool frequency Insufficient independent evidence

Micka enrolled 54 volunteers; the primary per-protocol report concerned 44. It found median stool frequency of four versus three weekly bowel movements with 12 g/day native chicory inulin and placebo. BENEO sponsored the work and employed two authors. The full original paper remains only partly accessible here; original indexed Methods and disclosures plus the abstract support this account. The registry was first posted in September 2015 after study completion in May 2012 (original abstract; indexed original report; registration record).

Puhlmann randomized 40 adults and reported 39 in the abstract. The Sensus-funded crossover used 12 g/day Frutafit HD, including three days at 6 g/day. Its controlled change estimate was an additional 0.53 weekly defecations; Table 1 explicitly flags the associated p-value as biased by an intervention–period interaction. Carryover and later unblinded analysis limit interpretation. Stool consistency did not differ significantly. Quality-of-life and symptom point estimates favored inulin, but the crossover’s controlled mean differences were smaller than the paper’s cited minimum important differences; statistically positive results do not establish that those average differences were clinically important. An exploratory first-period analysis found larger frequency and quality-of-life differences, but was not the full crossover comparison. This qualifies the signal without erasing it (original Table 1, Figure 4 and limitations).

These trials do not establish dependable sustained treatment for every cause of constipation or every inulin product. They concern selected participants and short periods; frequency, stool consistency, symptoms and quality of life are distinct outcomes (Micka; Puhlmann).

Routine use when bowel function is already normal Insufficient independent benefit

AHRQ’s 2025 report evaluated people without bowel dysfunction. Its inulin analysis found no clear stool-frequency advantage, so it does not answer treatment of chronic constipation. The related 2026 publication describes the review’s methods and government contract. Neither review applied this article’s industry-exclusion rule to all underlying trials; their pooled evidence is contextual rather than a purified independent estimate (AHRQ inulin results; original methods and declarations).

Watson’s two Sensus-funded trials excluded diagnosed constipation. Ten participants completed one trial and twenty the other. Frequency improved in the first but not the second, whose baseline bowel frequency often exceeded the intended range. The overall pooled frequency result was null; a low-frequency subgroup was favorable after an outlier exclusion. That exploratory subgroup does not make the entire second trial positive or establish chronic-constipation treatment (original Methods, tables and Results).

“More bowel movements” is not automatically a useful goal for a person who already passes comfortable stools normally.

Constipation-predominant IBS Insufficient

Akçalı randomized 34 adults to a 9.2 g/day 50:50 inulin/oligofructose blend or placebo for eight weeks. The symptom-severity change comparison favored the blend, while stool-form comparisons were null. Changes in overall IBS quality of life and depression did not show significant group–time interactions, despite some favorable within-group or final-group tests. Participants were blinded but researchers were not; the registry was posted after trial completion. Cash support and the unnamed private supplier’s payment terms remain unresolved. This is preliminary blend evidence, not an isolated-inulin treatment or confirmed mood benefit (original Tables 3, 5–6; registry dates and outcomes).

Gunn’s 19-completer acute IBS study found that adding psyllium reduced the MRI gas response to a 20 g inulin challenge. It did not establish significant overall pain or bloating relief or a lasting clinical regimen (original human outcomes).

A useful IBS trial needs a prespecified symptom responder outcome and enough follow-up to establish whether benefit outweighs discomfort. Fermentation measurements cannot substitute for that test.

Children's constipation Insufficient

The agave-inulin trial included 49 children with severe cerebral palsy and constipation; 37 completed, leaving ten in the prebiotic arm and seven on placebo. It found a favorable controlled hard-stool comparison but no established prebiotic frequency benefit. The main researcher furnished the products, including Ingredion agave inulin and maltodextrin; purchase or donation terms were not reported. A small specialized trial does not establish routine use in otherwise healthy children (original Methods and Table 3).

The population, formulation and care needs are too specific to turn this into an over-the-counter pediatric dosing recommendation.

Microbiome repair and broader disease claims Insufficient

Vandeputte analyzed 42 participants from Micka’s cohort, rather than a new independent clinical replication. The BENEO-sponsored analysis changed selected bacterial groups without a significant overall change in measured volatile-metabolite profiles, although one individual volatile compound increased. Microbe–symptom associations did not establish causality, disease prevention or a validated stool-test treatment threshold (original results and disclosures).

The digestive studies discussed here do not establish barrier repair, SIBO eradication, IBD treatment, cancer prevention or lasting recovery after antibiotics. Their measured outcomes and populations do not answer those claims. This is a focused review, not proof that every study of every inulin mixture has been identified. Oligofructose-enriched mixtures are considered separately in this series’ FOS review (adult constipation outcomes; microbiome outcomes; acute IBS outcomes).

What works and what does not

ClaimVerdictNotes
Adds a fermentable fiber to a food or supplementSupported as an ingredient propertyProduct composition determines the amount
A defined native chicory ingredient can carry a stool-frequency claim in the EUSupported as a legal factConditions are specific; the authority's standard differs from this funding screen
Independently established constipation treatmentNot established in the audited evidencePositive commercial trials remain relevant context
Reliably improves all IBS symptomsNot establishedSmall blend study and mechanistic gas experiments do not establish this
More bifidobacteria proves better healthUnsupported inferenceA biomarker needs a validated relationship to patient benefit
Every inulin/FOS/agave preparation works identicallyUnsupportedSource, chain lengths, processing and mixtures differ
Funding proves a study result is falseIncorrectConflicts and methodological validity are separate questions

Risks and side effects

AspectFindingSource
Gas and bloating Inulin increased MRI gas; coadministered psyllium reduced it without established overall pain/bloating relief Human MRI experiment
Tolerance at a given dose 26 healthy adults in single breakfast challenges; mostly mild symptoms, more after 10 g oligofructose. Full methods and funding not recovered Bonnema 2010 original abstract
AllergyA food-associated anaphylaxis case implicated an inulin–protein compound; a case report cannot estimate frequencyFranck 2005
Persistent or alarming symptomsConstipation with bleeding, constant abdominal pain, vomiting or inability to pass gas needs prompt medical assessmentNIDDK warning signs
Long-term and special-population safetyThe small, selected trials do not settle pregnancy, breastfeeding, serious illness or uncommon adverse effectsEvidence gap in the trials reviewed above

The allergy abstract concerns reactions to specific foods in one woman with an artichoke-allergy history. It suggests an inulin–protein compound; it does not estimate risk or establish that everyone with pollen/artichoke sensitivity reacts to every inulin preparation (original case abstract).

Safety: Breathing difficulty, throat swelling or collapse after a food or supplement requires emergency care (anaphylaxis guidance). Severe pain, persistent vomiting, bleeding or inability to pass gas warrants prompt assessment; do not dismiss these as a prebiotic “working” (constipation warning signs).

Interactions

Substance or conditionMechanism or concernSeverity/statusSource
Psyllium Reduced MRI gas after an acute inulin challenge No established overall pain/bloating relief or long-term regimen Gunn 2022
Medicines that contribute to constipationSymptoms may have a medication-related cause that adding inulin does not addressClinical assessment issue, not a demonstrated direct chemical interactionNIDDK causes
Oral medicines generallyIngredient-specific pharmacokinetic information was insufficient in this reviewUnknown; do not infer a safe universal spacing intervalNo comprehensive inulin-specific interaction trial identified
Known immediate reaction to an inulin-containing productRe-exposure could pose an allergy riskPotentially serious; product and allergen need assessmentFranck case report

This table is not an exhaustive interaction database. The reviewed papers do not establish that all medicines should be separated from inulin by a fixed number of hours, nor that inulin changes every medicine's absorption. Product-specific ingredients and the medicine's own instructions matter. A person taking medicines should have the actual formulation assessed by a clinician or pharmacist rather than apply a generic fiber rule.

Who should avoid unsupervised use

Persistent unexplained bowel symptoms and the warning signs above need assessment, rather than progressively larger unsupervised fiber doses (NIDDK warning signs). A previous immediate reaction to the product warrants allergy advice before re-exposure (NHS prevention guidance).

Pregnancy, breastfeeding, childhood, severe gastrointestinal disease and complex medical treatment warrant individualized assessment because the evidence reviewed here does not establish a general supplement regimen for those situations. That evidence gap does not amount to a claim that ordinary inulin-containing foods are universally unsafe.

Dosage and how to take

These are descriptions of research or legal claim conditions, not instructions for personal use. A studied dose does not establish an effective or safe dose for another preparation or population.

Use caseStudied doseDurationNotes
Selected low-frequency adults 12 g/day native chicory ingredient Four weeks per crossover period 54 enrolled, 44 per-protocol; BENEO-funded, retrospectively registered (Micka; registry)
Selected healthy low-frequency adults 10 g/day; first three days at 5 g/day Five weeks per period Mixed results; diagnosed constipation excluded, Sensus-funded (Watson)
Functional constipation 12 g/day; first three days at 6 g/day Four weeks per period Sensus-funded; carryover and analysis limitations (Puhlmann)
IBS-C blend 9.2 g/day of a 50:50 inulin/oligofructose mixture Eight weeks Combination, not isolated inulin; researcher unblinded, retrospectively registered (Akçalı; registry)
Children with cerebral palsy and constipation 4 g/day agave ingredient 28 days 37 completers; specialized small trial, not pediatric self-treatment instructions (García Contreras)
Acute IBS MRI experiment 20 g inulin, alone or with 20 g psyllium Single challenges Mechanistic protocol, not a long-term symptom regimen (Gunn)

NIDDK's general constipation advice favors a gradual change in dietary fiber and an appropriate fluid intake, with individual health circumstances considered. It does not prescribe this particular supplement or establish that adding more inulin is always better. NIDDK dietary guidance

Animal and in vitro evidence excluded from conclusions

Gunn’s laboratory fermentation experiments are mechanistic context, separate from the human MRI challenge and symptom outcomes. They do not establish treatment efficacy (original Methods and Discussion).

No animal study is used to establish a human benefit or a human harm rate in this article. This is important in both directions: an animal mechanism suggesting barrier protection would not prove treatment, and an inflammatory signal in an experimental model would not by itself prove that ordinary human intake causes disease.

Independent funding tracing

Follow the money

Research funding at a glance

Funding & backersSource & studyClaim & limits

28 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.

No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.

Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.

Who pays and who profits

The commercial interests include ingredient manufacturers, supplement and food brands, distributors and their investors or cooperative members. Their incentives include selling fiber ingredients and helping customers make attractive food claims. That is an analysis of an ordinary business incentive, not an allegation of misconduct.

BENEO is a division of the Südzucker group, whose parent is based in Mannheim, Germany. Its chicory-fiber operations include Belgium and Chile; the location of an international group does not identify where an individual retail batch was produced. Group structure, manufacturer's production disclosure

Südzucker’s displayed shareholder snapshot lists SZVG own/trust-held shares at 64.93%, Austrian investors through Zucker Invest at 10.24%, and free float at 24.83%. A separate effective ownership date is not given. These are disclosed holdings, not proof that a shareholder controlled any trial result (official shareholder disclosure).

Sensus is part of the Dutch Royal Cosun cooperative and now presents its business as Cosun Ingredients. The legacy news index dates the transition 1 July 2026; the current company announcement, dated 30 June, describes July 1 as the effective date. Its listed headquarters and production locations are Dutch. Grower ownership remains a commercial interest, not clinical independence (Cosun identity; locations; dated announcement record).

Cosun also reported that Dutch government agreements signed in December 2025 reserved up to €105 million for energy reduction and production modernization. That is a separate industrial-support relationship; it is not evidence that the government financed an inulin clinical trial or that the full amount had been paid. Cosun's February 2026 disclosure

Money map

Documented funding and ownership relationships for inulin. The full equivalent text and linked sources appear in the article.
Selected documented relationships; diagram dated 1 October 2026. Open the full-size map. Linked source details, author ties and procurement limits follow below.

The diagram shows selected documented relationships. The linked details below also retain unreported procurement and author-finance limits. Ownership percentages are the company’s displayed snapshot, whose separate effective date is not supplied.

Documented relationships:

How this changes the verdict

Manufacturer funding does not prove an incorrect result. However, it disqualifies the outcome from the independent benefit basis used here. The same rule applies to favorable, null and unfavorable studies, including manufacturer-donated products or other in-kind research support even when the cash funder is public. An arm’s-length purchase is not itself sponsorship. When procurement terms cannot be established, they remain unknown.

EFSA found a cause-and-effect relationship for the specified food claim across heterogeneous trials, often with stool frequency as a secondary outcome. It said the conclusion could be reached without one proprietary study, although that study informed the conditions of use. Neither this nor EU-budget agency status proves that the remaining studies were industry-free; complete older-trial finance and procurement remain unresolved (original relevant assessment).

The research is concentrated in European ingredient businesses and European trial settings, with smaller studies elsewhere. Nationality is not a quality grade; concentration matters because repeated papers from the same sponsor or cohort provide less independent corroboration than they may appear to.

Regulatory status

European Union

The EU permits the defined native chicory inulin food claim at 12 g/day, with the specified composition including mean DP of at least 9. It concerns normal bowel function through increased stool frequency, not IBS, SIBO or cancer treatment. The initial five-year BENEO restriction began in January 2016 and does not remain exclusive in 2026 (original regulation and annex).

United States

FDA's current dietary-fiber FAQ includes inulin and inulin-type fructans among ingredients for which it intends to exercise labeling enforcement discretion pending rulemaking. The agency's physiological assessment includes mineral-absorption evidence; this is not a finding that every inulin supplement treats constipation or IBS. FDA FAQ, FDA science assessment

A product's lawful sale, food-label status and evidence for a clinical claim are separate questions. Rules also vary by jurisdiction and formulation; these two regulatory summaries do not cover every country.

Frequently asked questions

Is inulin the same as FOS?

These are related, partly overlapping fructans with different chain distributions and processing. Identify hydrolyzed oligofructose, sucrose-derived short-chain FOS and any blend explicitly; the tested specification matters (FDA ingredient distinctions).

Why call the independent evidence insufficient when Europe permits a claim?

The EU assessment accepts a specified stool-frequency claim; this review separately excludes commercial support from its independent benefit basis. Funding does not prove a result false. The favorable assessment and the methodological/financial limits of individual studies must both be retained (EFSA assessment; original trial limitations).

Does more gas mean inulin is helping?

No. In the human MRI experiment, reducing gas did not establish significant overall pain or bloating relief. Fermentation alone is not a treatment endpoint, and substantial discomfort should not be dismissed as “detox” (original human outcomes).

Can a microbiome test tell me whether I need it?

The microbial study did not validate a stool-test threshold for selecting an effective inulin regimen. Its bacterial changes and symptom associations did not establish a causal treatment target (original analysis).

Should inulin replace treatment for constipation or IBS?

The reviewed studies do not establish a general replacement for constipation or IBS care. Results concern selected participants and specified preparations; the doses above describe research, not instructions to change treatment. Persistent or alarming symptoms need assessment (adult trial; IBS blend; warning signs).

Sources and funding notes

The scorecard records relationships identified in the sources actually read. Tiers 1–4 mean no relevant stake identified in those records, indirect relationships, an interested party and direct commercial research support or involvement; U means unresolved provenance. These are provisional editorial labels, not a complete ownership, procurement or personal-conflict certificate. Credibility A–D describes accountability and source incentives for the specified use, not clinical certainty. A corporate page may accurately document its own identity without establishing independent efficacy. Reported lack of conflicts does not resolve every unreported relationship.

SourceFunding or revenue and countryTier / credibility for this useAccuracy incentive and remaining limitation
Micka 2017 original report BENEO sponsor/two employees; contract-research authors; Germany 4 / C Original abstract and indexed Methods/disclosure only; full tables/attrition/finance partly unavailable; 54 enrolled/44 per-protocol, retrospective registration
Vandeputte 2017BENEO funds plus Belgian public fellowships; company employees; Belgium/Germany4 / CAccessible methods; same clinical cohort is not new replication
Watson 2019Sensus funded trials/statistics; UK public/charitable infrastructure also acknowledged; UK/Netherlands4 / CReports both positive and null trials; maker relationship remains
Puhlmann 2025 Sensus funding; current/former employees; Netherlands/Ireland/Denmark 4 / C Carryover-biased frequency analysis; later unblinded analysis; stool consistency null; controlled QOL/symptom point estimates below cited important-difference thresholds
Akçalı 2025 Turkish academic/hospital affiliations; no interests declared; unnamed private supplier U / B provisional Participant-only blinding and retrospective registration; cash/payment unknown; blend symptom signal but overall QOL/depression change tests null
García Contreras 2020 Mexico; no external funds/COI declared; researcher supplied named Ingredion/Biogaia materials U / B provisional 49 included/37 completed; controlled hard-stool signal, frequency not established; purchase/donation terms unknown
Gunn 2022 UK/Mexican public grants; food/pharma author ties; material-payment terms unknown 2 provisional / B Objective acute MRI; reduced gas does not establish pain/bloating relief or long-term treatment
Bonnema 2010 US academic authors plus Cargill regulatory/scientific-affairs author 4 / C Original abstract/partial affiliations only; full cash/procurement/methods not recovered; no chronic safe ceiling
Franck 2005 Nancy university hospital, France; funding/supply/COI unavailable in accessible abstract U / B provisional Single food-associated case; original abstract/title page only, not full immunologic-method or finance clearance; no incidence
AHRQ 2025 results US publicly commissioned Brown review 1 provisional at review level / A for report scope Normal bowel function; inulin-frequency analysis null; all underlying commercial/unknown trial finances not purified or traced
Balk 2026 report of the reviewAHRQ contract; US HHS/USDA sponsors; US/Australian authors; no conflicts reported1 provisionally at review level / BPrespecified synthesis; disclosures are self-reported and pooled studies need separate checks
EFSA 2015 opinion EU-budget agency, Parma; BENEO-Orafti application via Belgium 1 institutionally; mixed underlying evidence / A for assessment record Specified claim; heterogeneous trials, often secondary outcome; panel-personal interests and all older trial finances not fully audited
EU Regulation 2015/2314EU institutions and public budget; EU jurisdiction1 / A for lawAuthoritative legal text; not a separately funded trial
EU Regulation 2023/1141EU institutions; manufacturer claim application1 for legal record / ADocuments a different preparation's refused claim; cannot substitute for trial appraisal
FDA 2018 science reviewUS public agency; agency-wide user fees disclosed below2 institutionally / A for chemistry and regulatory reasoningTransparent review; manufacturer petitions and underlying studies retain their own interests
FDA current fiber FAQUS federal regulatory publication2 institutionally / A for legal-policy scopeDirect agency statement; no individual clinical recommendation
NIDDK constipation symptomsNIH public health information; United States1 provisionally / A for general safety contextExpert review and public mandate; page dated 2018, no named author conflict ledger
NIDDK dietary adviceNIH; United States1 provisionally / A for general contextPublic-facing guidance; not inulin-specific efficacy evidence
Südzucker structurePublicly listed producer group; Germany4 / C for corporate identityInvestor accountability; commercial self-description
Südzucker shareholding pageProducer investor relations; Germany, with Austrian shareholder link4 / C for disclosed holdingsNamed percentages; underlying snapshot date not separately supplied
BENEO production disclosureIngredient maker; Germany/Belgium, Chilean manufacturing4 / C for locations, D for marketingDirect knowledge of operations; feed/human health promotion excluded
Cosun corporate identityAgricultural cooperative; Netherlands4 / C for organizationMember accountability; promotional content and live member count not audited
Sensus locationsCosun ingredient business; Netherlands4 / C for location/namePrimary business record; no outcome validation
Sensus transition announcement record Seller-operated Netherlands business publication 4 / C for dated announcement Legacy index: 1 July 2026; current issuer story: 30 June 2026, effective 1 July; no clinical validation
Cosun February 2026 disclosureCooperative issuer; Netherlands4 / C for announced industrial supportPrimary self-report; reserved funds are not verified disbursement or trial financing
EFSA institutional funding FAQEU agency; Italy/EU1 / A for institutional factsOfficial budget/HQ description; not a panel-member conflict audit
FDA user-fee explanationUS regulatory agency2 / A for its funding systemPublic statutory framework; fee existence does not prove influence on this fiber decision
NIDDK budget informationNIH federal appropriations; United States1 / A for institutional fundingPublic budget documentation; no claim that all academic collaborators are conflict-free

These are source-specific checks, not a comprehensive audit of every investigator, donor, shareholder or supplier. Agency budget and academic affiliation are not automatic clinical endorsements; FDA user fees do not identify a payment for this inulin decision, and EFSA’s public budget does not make an applicant’s studies independent. Unreported amounts, original product-payment terms, retail-batch manufacturing and historical author relationships remain unknown.

Have a question — or want us to cover something?

Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.

We store your topic, message, optional email, and this page so we can manage and reply to the request. Do not include diagnoses, medications, or other sensitive medical information. See our Privacy Policy.